Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE American: ELMD) is a medical device company that develops, manufactures, and sells airway clearance therapy products, including the SmartVest® Airway Clearance System, for patients with compromised pulmonary function. Company news often highlights its role as a leader in airway clearance technologies and its focus on High Frequency Chest Wall Oscillation (HFCWO) therapy, particularly in the homecare setting.
Newsflow for Electromed frequently centers on financial results, such as quarterly and annual earnings releases that detail net revenues, operating income, net income, and segment performance in direct homecare and non-homecare markets. These announcements often discuss trends in referrals and approvals, sales force expansion, and gross margin dynamics, as well as commentary from management on operational execution and efficiency initiatives.
Investors can also expect corporate and capital markets updates, including announcements about share repurchase authorizations approved by the board of directors and index-related milestones, such as Electromed’s addition to the Russell 2000® and Russell 3000® indexes. The company issues press releases when it schedules earnings conference calls and webcasts, providing dial-in details and replay information.
Another recurring category of news involves investor conference participation. Electromed regularly announces its presence at events hosted by organizations such as Noble Capital Markets, LD Micro, Canaccord Genuity, and Investor Summit, where management presents the company’s airway clearance business and growth strategy to institutional and other investors.
For readers tracking ELMD, this news page provides a centralized view of Electromed’s earnings announcements, capital allocation decisions, index inclusions, and investor outreach activities, offering context on how the company is executing its strategy in the airway clearance therapy market.
Electromed (NYSE American: ELMD) has appointed Peter Horwich as Vice President, Marketing. Horwich brings over 20 years of experience in Medical Technology marketing, previously serving at Abiomed (now J&J MedTech) where he directed Global Strategic Marketing for Respiratory Therapies. His experience includes roles at Medtronic, Arizant, Entegris, and Guidant. CEO Jim Cunniff highlighted that this strategic appointment comes during a period of business growth and aims to drive therapy adoption for SmartVest Clearway to support revenue growth goals.
Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced a new $5.0 million share repurchase authorization effective September 11, 2024. This follows the completion of their previous repurchase program in Q4 fiscal 2024. The company's board will determine the timing and amount of repurchases based on market conditions. Repurchases may be made through various means, including open market transactions and block trades.
CEO Jim Cunniff stated that this decision follows Electromed's record performance in fiscal 2024 and reflects the board's confidence in future growth. The company's strong revenue growth and profitability are generating robust free cash flow, allowing for shareholder value creation while continuing business investments. Management believes the stock is undervalued given their strong financial results.
Electromed, Inc. (NYSE American: ELMD) reported record financial results for Q4 and FY 2024. Highlights include:
- Q4 net revenues increased 9.0% to $14.8 million
- Q4 operating income up 56.3% to $2.3 million
- Q4 net income reached $1.8 million or $0.20 per diluted share
- FY 2024 net revenue grew 13.8% to $54.7 million
- FY 2024 operating income increased 64.2% to $6.6 million
- FY 2024 net income totaled $5.2 million or $0.58 per diluted share
The company attributed growth to investments in commercial infrastructure and market development initiatives. As of June 30, 2024, Electromed had $16.1 million in cash, $23.3 million in accounts receivable, and no debt.
Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its upcoming financial results release and conference call for the fourth quarter of fiscal 2024. The company will issue its financial results press release on August 27, 2024, after the stock market closes. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
Interested parties can participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). A live webcast will be accessible on Electromed's website in the Investor Relations section. For those unable to listen live, a replay will be available by phone and online.
Electromed, a leader in innovative airway clearance technologies, announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference in Boston from August 13-15, 2024. Jim Cunniff, President and CEO, and Brad Nagel, CFO, will present on Wednesday, August 14, 2024, at 2:30 p.m. Eastern Time.
The presentation will be available via live and archived webcast on Electromed's website under Events & Presentations. Additionally, Electromed has published an updated investor presentation deck for review, accessible on their website and the SEC website.
Electromed, known for its innovative airway clearance technologies, announced that its top executives, President and CEO Jim Cunniff and CFO Brad Nagel, will attend the 2024 Sidoti June Small-Cap Virtual Conference. This event is scheduled for June 12-13, 2024. Electromed will present at 1:45 p.m. ET on June 12, 2024. A live and archived webcast of their presentation will be accessible via the Electromed website.
Electromed, Inc. achieves record revenue in the third quarter of fiscal year 2024, with a 15% increase to $13.9 million compared to the prior year. Operating income rises by 54%, net income reaches $1.49 million, and cash balance grows to $11.7 million. The company's direct homecare business revenue increases by 12%, showing strong growth and operational efficiency. The gross profit margin remains stable at 75%. Electromed continues to focus on driving adoption of its products, enhancing shareholder value, and sustaining operating leverage for profitability.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
